Alwin KrÃ¤mer

List of Publications by Year
in descending order

56 papers	7,829 citations	117571 34 h-index	161767 54 g-index
57 all docs	57 docs citations	57 times ranked	10840 citing authors

#	Article	IF	Citations
1	CEBPA mutations in 4708 patients with acute myeloid leukemia: differential impact of bZIP and TAD mutations on outcome. Blood, 2022, 139, 87-103.	0.6	82
2	Differential impact of IDH1/2 mutational subclasses on outcome in adult AML: results from a large multicenter study. Blood Advances, 2022, 6, 1394-1405.	2.5	17
3	Molecular profiling and clinical implications of patients with acute myeloid leukemia and extramedullary manifestations. Journal of Hematology and Oncology, 2022, 15, 60.	6.9	17
4	Clinical Outcomes in Patients with FLT3-ITD-Mutated Relapsed/Refractory Acute Myelogenous Leukemia Undergoing Hematopoietic Stem Cell Transplantation after Quizartinib or Salvage Chemotherapy in the QuANTUM-R Trial. Transplantation and Cellular Therapy, 2021, 27, 153-162.	0.6	16
5	Concentrationâ€“QTc analysis of quizartinib in patients with relapsed/refractory acute myeloid leukemia. Cancer Chemotherapy and Pharmacology, 2021, 87, 513-523.	1.1	4
6	Sorafenib or placebo in patients with newly diagnosed acute myeloid leukaemia: long-term follow-up of the randomized controlled SORAML trial. Leukemia, 2021, 35, 2517-2525.	3.3	40
7	Loss-of-Function Mutations of BCOR Are an Independent Marker of Adverse Outcomes in Intensively Treated Patients with Acute Myeloid Leukemia. Cancers, 2021, 13, 2095.	1.7	7
8	Impact of PTPN11 mutations on clinical outcome analyzed in 1529 patients with acute myeloid leukemia. Blood Advances, 2021, 5, 3279-3289.	2.5	21
9	Allogeneic hematopoietic cell transplantation improves outcome of adults with t(6;9) acute myeloid leukemia: results from an international collaborative study. Haematologica, 2020, 105, 161-169.	1.7	15
10	Population Pharmacokinetic Analysis of Quizartinib in Healthy Volunteers and Patients With Relapsed/Refractory Acute Myeloid Leukemia. Journal of Clinical Pharmacology, 2020, 60, 1629-1641.	1.0	2
11	Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial. Lancet Oncology, The, 2019, 20, 984-997.	5.1	330
12	Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial. Lancet Oncology, The, 2018, 19, 1668-1679.	5.1	250
13	Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial. Lancet Oncology, The, 2018, 19, 889-903.	5.1	205
14	Prediction of acute myeloid leukaemia risk in healthy individuals. Nature, 2018, 559, 400-404.	13.7	617
15	Synthesis and formulation studies of griseofulvin analogues with improved solubility and metabolic stability. European Journal of Medicinal Chemistry, 2017, 130, 240-247.	2.6	14
16	Marker chromosomes can arise from chromothripsis and predict adverse prognosis in acute myeloid leukemia. Blood, 2017, 129, 1333-1342.	0.6	57
17	Asymmetric Centriole Numbers at Spindle Poles Cause Chromosome Missegregation in Cancer. Cell Reports, 2017, 20, 1906-1920.	2.9	49
18	The Addition of Sorafenib to Standard AML Treatment Results in a Substantial Reduction in Relapse Risk and Improved Survival. Updated Results from Long-Term Follow-up of the Randomized-Controlled Soraml Trial. Blood, 2017, 130, 721-721.	0.6	20

#	Article	IF	Citations
19	Pharmacological Inhibition of Centrosome Clustering by Slingshot-Mediated Cofilin Activation and Actin Cortex Destabilization. Cancer Research, 2016, 76, 6690-6700.	0.4	24
20	Centrosome amplification, chromosomal instability and cancer: mechanistic, clinical and therapeutic issues. Chromosome Research, 2016, 24, 105-126.	1.0	59
21	Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial. Lancet Oncology, The, 2015, 16, 1691-1699.	5.1	347
22	Lack of centrioles and primary cilia inSTIL^{â^'/â^'}mouse embryos. Cell Cycle, 2014, 13, 2859-2868.	1.3	36
23	Sorafenib in Combination With Intensive Chemotherapy in Elderly Patients With Acute Myeloid Leukemia: Results From a Randomized, Placebo-Controlled Trial. Journal of Clinical Oncology, 2013, 31, 3110-3118.	0.8	290
24	Clonal Heterogeneity As Detected by Metaphase Karyotyping Is an Indicator of Poor Prognosis in Acute Myeloid Leukemia. Journal of Clinical Oncology, 2013, 31, 3898-3905.	0.8	63
25	The novel actin/focal adhesion-associated protein MISP is involved in mitotic spindle positioning in human cells. Cell Cycle, 2013, 12, 1457-1471.	1.3	37
26	STIL is required for centriole duplication in human cells. Journal of Cell Science, 2012, 125, 1353-1362.	1.2	167
27	Survey and analysis of the efficacy and prescription pattern of sorafenib in patients with acute myeloid leukemia. Leukemia and Lymphoma, 2012, 53, 1062-1067.	0.6	23
28	Overexpression of EVI1 interferes with cytokinesis and leads to accumulation of cells with supernumerary centrosomes in G_{0/1}phase. Cell Cycle, 2012, 11, 3492-3503.	1.3	21
29	Disparate SAR Data of Griseofulvin Analogues for the Dermatophytes Trichophyton mentagrophytes, T. rubrum, and MDA-MB-231 Cancer Cells. Journal of Medicinal Chemistry, 2012, 55, 652-660.	2.9	44
30	GF-15, a Novel Inhibitor of Centrosomal Clustering, Suppresses Tumor Cell Growth In Vitro and In Vivo. Cancer Research, 2012, 72, 5374-5385.	0.4	64
31	Mechanisms and Consequences of Centrosome Clustering in Cancer Cells. , 2012, , 285-305.		3
32	Centrosome clustering and chromosomal (in)stability: A matter of life and death. Molecular Oncology, 2011, 5, 324-335.	2.1	98
33	Molecular docking and pharmacogenomics of Vinca alkaloids and their monomeric precursors, vindoline and catharanthine. Biochemical Pharmacology, 2011, 81, 723-735.	2.0	37
34	(+)-Geodin fromAspergillus terreus. Acta Crystallographica Section C: Crystal Structure Communications, 2011, 67, o125-o128.	0.4	11
35	Cep63 Recruits Cdk1 to the Centrosome: Implications for Regulation of Mitotic Entry, Centrosome Amplification, and Genome Maintenance. Cancer Research, 2011, 71, 2129-2139.	0.4	52
36	The Stil protein regulates centrosome integrity and mitosis through suppression of Chfr. Journal of Cell Science, 2011, 124, 532-539.	1.2	42

#	Article	IF	Citations
37	Cytarabine Dose of 36 g/m² Compared With 12 g/m² Within First Consolidation in Acute Myeloid Leukemia: Results of Patients Enrolled Onto the Prospective Randomized AML96 Study. Journal of Clinical Oncology, 2011, 29, 2696-2702.	0.8	94
38	Chromosomal instability correlates with poor outcome in patients with myelodysplastic syndromes irrespectively of the cytogenetic risk group. Journal of Cellular and Molecular Medicine, 2010, 14, 895-902.	1.6	52
39	DNA Damage-Induced Degradation of Cdc25A Does Not Lead to Inhibition of Cdk2 Activity in Mouse Embryonic Stem Cells. Stem Cells, 2010, 28, 450-461.	1.4	15
40	Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease. Nature Medicine, 2010, 16, 198-204.	15.2	727
41	Proteins Required for Centrosome Clustering in Cancer Cells. Science Translational Medicine, 2010, 2, 33ra38.	5.8	152
42	Cell-Cycle Regulation in Embryonic Stem Cells: Centrosomal Decisions on Self-Renewal. Stem Cells and Development, 2010, 19, 1663-1678.	1.1	23
43	Centrosomes in Checkpoint Responses. , 2010, , 53-67.		0
44	Microcephalin and pericentrin regulate mitotic entry via centrosome-associated Chk1. Journal of Cell Biology, 2009, 185, 1149-1157.	2.3	83
45	Synthesis and Structureâ^'Activity Relationship of Griseofulvin Analogues as Inhibitors of Centrosomal Clustering in Cancer Cells. Journal of Medicinal Chemistry, 2009, 52, 3342-3347.	2.9	64
46	DNA Damage-Induced Accumulation of Centrosomal Chk1 Contributes to its Checkpoint Function. Cell Cycle, 2007, 6, 2541-2548.	1.3	63
47	Identification of Griseofulvin as an Inhibitor of Centrosomal Clustering in a Phenotype-Based Screen. Cancer Research, 2007, 67, 6342-6350.	0.4	166
48	Expression of centrosome-associated gene products is linked to tetraploidization in mantle cell lymphoma. International Journal of Cancer, 2007, 120, 1669-1677.	2.3	21
49	Structure meets functionâ€"Centrosomes, genome maintenance and the DNA damage response. Experimental Cell Research, 2006, 312, 2633-2640.	1.2	97
50	Chk1-Dependent Regulation of Cdc25B Functions to Coordinate Mitotic Events. Cell Cycle, 2006, 5, 2543-2547.	1.3	49
51	DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature, 2005, 434, 864-870.	13.7	2,491
52	Centrosome aberrations in hematological malignancies. Cell Biology International, 2005, 29, 375-383.	1.4	58
53	Checking Out the Centrosome. Cell Cycle, 2004, 3, 1390-1393.	1.3	75
54	Centrosome-associated Chk1 prevents premature activation of cyclin-Bâ€"Cdk1 kinase. Nature Cell Biology, 2004, 6, 884-891.	4.6	296

#	Article	IF	Citations
55	Centrosomal aberrations in primary invasive breast cancer are associated with nodal status and hormone receptor expression. International Journal of Cancer, 2003, 107, 346-352.	2.3	55
56	Centrosome aberrations in acute myeloid leukemia are correlated with cytogenetic risk profile. Blood, 2003, 101, 289-291.	0.6	67